CN105384687B - 喹啉酮类化合物及其在药物中应用 - Google Patents
喹啉酮类化合物及其在药物中应用 Download PDFInfo
- Publication number
- CN105384687B CN105384687B CN201510557206.9A CN201510557206A CN105384687B CN 105384687 B CN105384687 B CN 105384687B CN 201510557206 A CN201510557206 A CN 201510557206A CN 105384687 B CN105384687 B CN 105384687B
- Authority
- CN
- China
- Prior art keywords
- methyl
- hydroxy
- oxo
- dihydroquinoline
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c(c(*)c1C(O)=C2C(NCC(O)=O)=O)c(*)c(*)c1N(*)C2=O Chemical compound *c(c(*)c1C(O)=C2C(NCC(O)=O)=O)c(*)c(*)c1N(*)C2=O 0.000 description 4
- YWVWMONXVDELOX-UHFFFAOYSA-N CC(C(N(C)C1=[I]C=CC(OC(C=CC2)=CC2=[F])=CC=C11)=[O]=C)=C1O Chemical compound CC(C(N(C)C1=[I]C=CC(OC(C=CC2)=CC2=[F])=CC=C11)=[O]=C)=C1O YWVWMONXVDELOX-UHFFFAOYSA-N 0.000 description 1
- WKACUVXGXQFRMZ-KPEOIQKJSA-N CN(c(cc(cc1)OC/C=C(\C=C(/C=C)\Cl)/F)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)OC/C=C(\C=C(/C=C)\Cl)/F)c1C(O)=C1C(NCC(O)=O)=O)C1=O WKACUVXGXQFRMZ-KPEOIQKJSA-N 0.000 description 1
- QRBJEOYTJIOYRT-UHFFFAOYSA-N CN(c(cc(cc1)Oc(cc2)ccc2OC)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc(cc2)ccc2OC)c1C(O)=C1C(NCC(O)=O)=O)C1=O QRBJEOYTJIOYRT-UHFFFAOYSA-N 0.000 description 1
- KZVACICDHIJYPM-UHFFFAOYSA-N CN(c(cc(cc1)Oc(cccc2)c2OC(F)(F)F)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc(cccc2)c2OC(F)(F)F)c1C(O)=C1C(NCC(O)=O)=O)C1=O KZVACICDHIJYPM-UHFFFAOYSA-N 0.000 description 1
- DXSIQMMMGZQOEX-UHFFFAOYSA-N CN(c(cc(cc1)Oc2cc(Cl)ccc2F)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2cc(Cl)ccc2F)c1C(O)=C1C(NCC(O)=O)=O)C1=O DXSIQMMMGZQOEX-UHFFFAOYSA-N 0.000 description 1
- ICXAYMXZQDDPME-UHFFFAOYSA-N CN(c(cc(cc1)Oc2cc(F)ccc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2cc(F)ccc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O ICXAYMXZQDDPME-UHFFFAOYSA-N 0.000 description 1
- UOXGSAQMWYGJJW-UHFFFAOYSA-N CN(c(cc(cc1)Oc2cc(cccc3)c3cc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2cc(cccc3)c3cc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O UOXGSAQMWYGJJW-UHFFFAOYSA-N 0.000 description 1
- YWAUYPYFFKKBFV-UHFFFAOYSA-N CN(c(cc(cc1)Oc2ccncc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2ccncc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O YWAUYPYFFKKBFV-UHFFFAOYSA-N 0.000 description 1
- UZGBENGFNVWPQF-UHFFFAOYSA-N CN(c(ccc(Oc1ccccc1)c1)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(ccc(Oc1ccccc1)c1)c1C(O)=C1C(NCC(O)=O)=O)C1=O UZGBENGFNVWPQF-UHFFFAOYSA-N 0.000 description 1
- LHOARXWSUMAVHS-UHFFFAOYSA-N CN(c1cc(Oc(cccc2)c2Cl)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c1cc(Oc(cccc2)c2Cl)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O LHOARXWSUMAVHS-UHFFFAOYSA-N 0.000 description 1
- JRJDZFSTCZSDLQ-UHFFFAOYSA-N CN(c1cc(Oc(cccc2)c2F)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c1cc(Oc(cccc2)c2F)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O JRJDZFSTCZSDLQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510557206.9A CN105384687B (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其在药物中应用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410442574 | 2014-09-02 | ||
| CN2014104425744 | 2014-09-02 | ||
| CN201510557206.9A CN105384687B (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其在药物中应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105384687A CN105384687A (zh) | 2016-03-09 |
| CN105384687B true CN105384687B (zh) | 2018-05-01 |
Family
ID=55417512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510557206.9A Active CN105384687B (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其在药物中应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10065928B2 (https=) |
| EP (1) | EP3190104B1 (https=) |
| JP (1) | JP6506390B2 (https=) |
| CN (1) | CN105384687B (https=) |
| AU (1) | AU2015311333B2 (https=) |
| CA (1) | CA2959688C (https=) |
| ES (1) | ES2898476T3 (https=) |
| WO (1) | WO2016034108A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269176A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269178A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
| CN108069952B (zh) * | 2016-11-08 | 2022-09-27 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其在药物中应用 |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CN108285460A (zh) * | 2017-01-09 | 2018-07-17 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的药用盐及其制备方法与用途 |
| JP6999469B2 (ja) * | 2018-03-28 | 2022-01-18 | 東京応化工業株式会社 | 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子 |
| CN111269177B (zh) * | 2019-11-28 | 2023-05-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型 |
| EP4067346B1 (en) * | 2019-11-28 | 2025-12-31 | Sunshine Lake Pharma Co., Ltd. | CRYSTALLINE FORM OF ACETIC ACID OF 2-(4-HYDROXY-1-METHYL-2-OXO-7-PHENOXY-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDO) |
| WO2022184159A1 (zh) * | 2021-03-05 | 2022-09-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010663A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010664A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN114989085B (zh) * | 2022-05-23 | 2023-11-24 | 安徽医科大学 | 一种芳基内酰胺环类化合物、药物组合物及其应用 |
| CN117159549B (zh) * | 2023-10-11 | 2025-02-14 | 中国药科大学 | 一种酯类化合物的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2528232C (en) | 2003-06-06 | 2010-05-25 | Fibrogen, Inc. | Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| EP1849465A4 (en) * | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| WO2006094292A2 (en) | 2005-03-02 | 2006-09-08 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| JP5202327B2 (ja) * | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| EP2476669A1 (en) | 2006-01-27 | 2012-07-18 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| CN103497184A (zh) | 2006-04-04 | 2014-01-08 | 菲布罗根有限公司 | 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物 |
| WO2007136990A2 (en) | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JO2934B1 (en) | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| BRPI0713350B1 (pt) | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| EP2111399A2 (en) | 2006-12-18 | 2009-10-28 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| US8048892B2 (en) | 2006-12-18 | 2011-11-01 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| EP2142509B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| CA2683758A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| EP2155680B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Indanone derivatives that inhibit prolyl hydroxylase |
| ES2389063T3 (es) | 2007-05-04 | 2012-10-22 | Amgen, Inc | Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa |
| CA2696725A1 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039322A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009070644A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20100305133A1 (en) | 2007-11-30 | 2010-12-02 | Smithkline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| WO2009086044A1 (en) | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| CN101951777A (zh) | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢呋喃并吡啶酮 |
| CA2714111A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydro-1h-pyrrolo fused pyridones |
| JP2011513222A (ja) | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロチエノピリジン |
| EP2294066B9 (en) | 2008-04-28 | 2015-03-11 | Janssen Pharmaceutica, N.V. | Benzoimidazoles as prolyl hydroxylase inhibitors |
| WO2009134847A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20110039895A1 (en) | 2008-04-30 | 2011-02-17 | Glaxo Smith Kline LLC., a corporation | Prolyl hydroxylase inhibitors |
| JP2011525924A (ja) | 2008-06-25 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| EP2326178A4 (en) | 2008-08-21 | 2012-10-24 | Glaxosmithkline Llc | INHIBITORS OF PROLYL-HYDROXYLASE |
| JP2012500850A (ja) | 2008-08-25 | 2012-01-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| EP2396316B1 (en) | 2009-02-10 | 2015-07-01 | Janssen Pharmaceutica, N.V. | Quinazolinones as prolyl hydroxylase inhibitors |
| AU2010273101B2 (en) | 2009-07-15 | 2016-02-25 | Beijing Betta Pharmaceuticals Co., Ltd. | Compounds as hypoxia mimetics, and compositions, and uses thereof |
| SI2455381T1 (sl) | 2009-07-17 | 2014-08-29 | Japan Tobacco Inc. | Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| TWI500623B (zh) | 2009-10-13 | 2015-09-21 | Torrent Pharmaceuticals Ltd | 新穎稠合噻唑及噁唑嘧啶酮 |
| WO2011056725A1 (en) | 2009-11-05 | 2011-05-12 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| US8541430B2 (en) | 2009-11-27 | 2013-09-24 | Torrent Pharmaceuticals Limited | Fused thiazolo and oxazolo pyrimidinones |
| AU2011289230B2 (en) | 2010-08-13 | 2014-09-04 | Janssen Pharmaceutica Nv | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| EP2717870B1 (en) | 2011-06-06 | 2017-09-27 | Akebia Therapeutics Inc. | Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer |
| NO2686520T3 (https=) | 2011-06-06 | 2018-03-17 | ||
| AU2012289563A1 (en) | 2011-07-29 | 2014-03-13 | Beijing Betta Pharmaceuticals Co., Ltd | Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof |
| AU2013229922B2 (en) | 2012-03-09 | 2017-09-28 | Kyntra Bio, Inc. | 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors |
| EP2872487B1 (en) | 2012-07-16 | 2017-04-26 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| MX360858B (es) | 2012-07-30 | 2018-11-20 | Taisho Pharmaceutical Co Ltd | Compuesto heterocíclico que contiene nitrógeno parcialmente saturado. |
| CA2881806A1 (en) | 2012-08-23 | 2014-02-27 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compound |
| WO2014102818A1 (en) * | 2012-12-24 | 2014-07-03 | Cadila Healthcare Limited | Novel quinolone derivatives |
| CA2899024C (en) | 2013-01-24 | 2022-01-04 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
-
2015
- 2015-09-01 JP JP2017512046A patent/JP6506390B2/ja active Active
- 2015-09-01 AU AU2015311333A patent/AU2015311333B2/en active Active
- 2015-09-01 CA CA2959688A patent/CA2959688C/en active Active
- 2015-09-01 EP EP15837609.5A patent/EP3190104B1/en active Active
- 2015-09-01 CN CN201510557206.9A patent/CN105384687B/zh active Active
- 2015-09-01 US US15/502,499 patent/US10065928B2/en active Active
- 2015-09-01 WO PCT/CN2015/088799 patent/WO2016034108A1/zh not_active Ceased
- 2015-09-01 ES ES15837609T patent/ES2898476T3/es active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269176A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269178A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2898476T3 (es) | 2022-03-07 |
| JP2017525737A (ja) | 2017-09-07 |
| AU2015311333B2 (en) | 2017-11-16 |
| CA2959688C (en) | 2024-02-27 |
| US10065928B2 (en) | 2018-09-04 |
| JP6506390B2 (ja) | 2019-04-24 |
| AU2015311333A1 (en) | 2017-02-16 |
| EP3190104B1 (en) | 2021-10-27 |
| WO2016034108A1 (zh) | 2016-03-10 |
| EP3190104A1 (en) | 2017-07-12 |
| CA2959688A1 (en) | 2016-03-10 |
| CN105384687A (zh) | 2016-03-09 |
| US20170247332A1 (en) | 2017-08-31 |
| EP3190104A4 (en) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105384687B (zh) | 喹啉酮类化合物及其在药物中应用 | |
| CN109400625B (zh) | 稠合双环类化合物及其在药物中的应用 | |
| KR101551238B1 (ko) | 신규한 ｈｉｖ 역전사효소 억제제 | |
| WO2023061463A1 (zh) | 新的嘧啶并吡啶化合物、其药物组合物及其用途 | |
| WO2015158310A1 (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
| CN117222654A (zh) | Kras g12c抑制剂和其用途 | |
| CN112771027A (zh) | 溶血磷脂酸受体拮抗剂及其制备方法 | |
| CN118843630A (zh) | 作为pkmyt1抑制剂的杂芳族化合物及其用途 | |
| CN105636953A (zh) | 1,4-二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 | |
| WO2020011246A1 (zh) | 含苯环的化合物、其制备方法及应用 | |
| EA025863B1 (ru) | Карбазолкарбоксамидные соединения | |
| TW202015687A (zh) | 嘧啶衍生物之醫藥鹽及治療病症之方法 | |
| TW202003487A (zh) | 經取代的２，２＇—聯嘧啶基化合物、其類似物及其使用方法 | |
| WO2017190637A1 (zh) | 用于抑制蛋白酪氨酸激酶活性的稠合嘧啶类化合物 | |
| WO2020259703A1 (zh) | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 | |
| WO2024222660A1 (zh) | 酰胺类化合物、包含其的药物组合物及其用途 | |
| CN108069952B (zh) | 喹啉酮类化合物及其在药物中应用 | |
| CN108069957B (zh) | 脯氨酰羟化酶抑制剂及其用途 | |
| WO2022143610A1 (zh) | 新型酰胺吡咯类化合物及其在药物中的应用 | |
| WO2011124093A1 (zh) | 双环喹诺酮类化合物及其制备和应用 | |
| WO2024099225A1 (zh) | Ulk抑制剂 | |
| WO2023274396A1 (zh) | 苯并氮杂环类化合物及其在药物中的应用 | |
| CN117355506A (zh) | 包括氮杂环丁烷环脲的rip1调节剂、其制备和用途 | |
| CN109320553A (zh) | 用于抗病毒的新型核苷类逆转录酶抑制剂 | |
| HK40105619A (zh) | 包括氮杂环丁烷环脲的rip1调节剂、其制备和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160309 Assignee: Nianyan Pharmaceutical (Shanghai) Co.,Ltd. Assignor: SUNSHINE LAKE PHARMA Co.,Ltd. Contract record no.: X2021980013023 Denomination of invention: Quinolone compounds and their application in medicine Granted publication date: 20180501 License type: Exclusive License Record date: 20211124 |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan) Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| EC01 | Cancellation of recordation of patent licensing contract | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Nianyan Pharmaceutical (Shanghai) Co.,Ltd. Assignor: SUNSHINE LAKE PHARMA Co.,Ltd. Contract record no.: X2021980013023 Date of cancellation: 20241010 |